Crescita Therapeutics Inc.
CTX.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.64M | 2.99M | 3.71M | 3.47M | 2.26M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.64M | 2.99M | 3.71M | 3.47M | 2.26M |
| Cost of Revenue | 1.19M | 1.35M | 1.92M | 1.22M | 1.14M |
| Gross Profit | 1.44M | 1.63M | 1.79M | 2.25M | 1.12M |
| SG&A Expenses | 1.96M | 2.06M | 1.92M | 1.89M | 1.76M |
| Depreciation & Amortization | 228.80K | 222.20K | 285.60K | 278.60K | 281.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.49M | 3.75M | 4.25M | 3.56M | 3.29M |
| Operating Income | -859.30K | -763.00K | -542.20K | -83.10K | -1.03M |
| Income Before Tax | -759.60K | -676.70K | -464.30K | 34.50K | -955.80K |
| Income Tax Expenses | -- | -- | -- | 144.80K | -- |
| Earnings from Continuing Operations | -759.60K | -676.70K | -464.30K | -110.30K | -955.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -759.60K | -676.70K | -464.30K | -110.30K | -955.80K |
| EBIT | -859.30K | -763.00K | -542.20K | -83.10K | -1.03M |
| EBITDA | -630.50K | -540.80K | -256.60K | 118.90K | -748.50K |
| EPS Basic | -0.04 | -0.03 | -0.02 | -0.01 | -0.05 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.01 | 0.00 | -0.03 |
| EPS Diluted | -0.04 | -0.04 | -0.02 | -0.01 | -0.05 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.01 | 0.00 | -0.03 |
| Average Basic Shares Outstanding | 19.27M | 19.44M | 19.59M | 19.99M | 20.37M |
| Average Diluted Shares Outstanding | 19.27M | 19.44M | 19.59M | 19.99M | 20.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
